A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia
Abstract
In a prospective, multicenter, double-blind, randomized clinical trial, we compared the efficacy of piperacillin-tazobactam (4.5 g 3 times daily intravenously) plus placebo versus piperacillin-tazobactam plus amikacin (7.5 mg/kg twice daily intravenously) for the treatment of 760 febrile, adult pati …
Keywords
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
treatment outcome
research support
non-u.s. gov't
adult
female
male
adolescent
aged
middle aged
Comparative Study
Prospective Studies
Clinical Trial
Randomized Controlled Trial
Double-Blind Method
Multicenter Study
drug therapy
neutropenia / complications*
neutropenia / chemically induced
fever / etiology*
bacterial infections / drug therapy*
anti-bacterial agents / therapeutic use*
combination / therapeutic use*
pmid:11565068
doi:10.1086/322646
a del favero
f menichetti
gruppo italiano malattie ematologiche dell'adulto (gimema) infection program
amikacin / therapeutic use*
bacterial infections / physiopathology
penicillanic acid / analogs & derivatives
penicillanic acid / therapeutic use*
piperacillin / therapeutic use*
piperacillin
tazobactam drug combination
Access
Citation
ID:
118063
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
118063
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet